A：In 2025, the company's total revenue and profit remained solid overall. Since its listing in 2018, the compound growth rate of revenue and total profit has been 12.1 and 5.4, respectively. In 2025, the company achieved operating income of 7.187 billion billion yuan, down 5.1 year-on-year, mainly due to the impact of nuclear medical equipment collection revenue decreased. The total profit was 1.004 billion yuan, and the net profit attributable to the parent company was 0.327 billion yuan, a decrease of 19.66 year-on-year, mainly due to the impact of the payment of taxes and late fees by Zhonghe Hedewei. After deducting the impact of supplementary taxes, the net profit attributable to the parent company was 0.457 billion yuan, up 12.5 percent year-on-year.

A：Among the company's operating income achieved in 2025, the nuclear pharmaceutical business contributed the most, with revenue of 4.02 billion yuan, accounting for 56%, an increase of one percentage point year-on-year. Radioactive source business realized revenue of 0.81 billion yuan, accounting for 11%; Medical equipment realized revenue of 0.6 billion yuan, accounting for 8%.

A：In 2025, the company achieved a gross profit of 3.62 billion yuan, a slight decrease, mainly due to the decline in revenue. Among them, the nuclear drug business contributed gross profit of 2.82 billion yuan, the radioactive source business contributed gross profit of 0.4 billion yuan, and the medical equipment business contributed gross profit of 0.16 billion yuan. The gross profit of each business segment rose and fell, and the overall gross profit decreased year-on-year, mainly due to the decline in revenue from the nuclear drug business and nuclear medical equipment business.

A：The company has made new progress in the field of nuclear drug research and development, such as the submission of two nuclear drug registration applications for neuroendocrine tumor diagnosis and Helicobacter pylori detection, and several nuclear drugs are undergoing phase III clinical trials. In the field of nuclide preparation, high-concentration carbon monoxide gas and carbon -13 urea products have been officially listed, realizing the independent control of the whole industrial chain of medical carbon stable isotopes from key raw materials to end products. In addition, the company has also made achievements in the field of radioactive sources, such as the on-line thickness gauge technology for wide and thick hot-rolled plates, which has reached the international advanced level.

A：In the domestic market, to achieve a normal supply with Macau, and signed a full-process service contract with Hong Kong, the knife occupies a higher share of the domestic market. In the international market, respiratory diagnostic products have obtained registration certificates in 12 countries, including Saudi Arabia and Germany, and the drug production line and Malaysia project have entered the trial operation stage. They have once again won the bid for the equipment supply project of Bangladesh's Baian residential auxiliary station, and signed a memorandum of understanding on cooperation in the isotope field with Brazil's National Nuclear Energy Commission.

A：In terms of base construction, the North China Pharmaceutical Base has obtained the first wave of production opinions, the East China Pharmaceutical Base has obtained the Fu 'an Certificate, the first phase of the Anhui City Stable Isotope Base has been fully put into operation, the second phase of construction has started, the Qinshan Isotope Base has completed the completion and acceptance, and the Jiajiang Radioactive Source Base has been completed and put into operation in the first phase, and an application has been submitted in the second phase. In terms of medical centers, Guiyang and Xinjiang medical centers have been put into production, with a total of 29 and 8 medical centers under construction. In the field of service center, the main structure of Tianjin Irradiation Center is capped and is expected to be put into operation in 2026.

A：The company has fully introduced the excellent performance model and established a market-oriented scientific and technological innovation system and a trinity market development system. We will add one national-level specialized and special new giant enterprise and one national-level single champion enterprise, and five provincial and ministerial-level specialized and special new enterprises. At the same time, the company has performed well in ESG, and has been rated as excellent for three consecutive years. It has been selected as an excellent practice unit for the first time, and has been ranked among the 100 pioneers of China's ESG listed companies in 2025.

A：In the field of new drug research and development, the company achieved significant breakthroughs during the 14th Five-Year Plan period, especially in the treatment of abdominal diseases, such as the layout of the German sulfide colloid and bone transfer sodium fluoride and other projects. At the same time, the company has made key progress in audit research and development, successfully realized the localization of carbon 13, and actively expanded foreign markets. At present, the company has 66 registration certificates in many countries. In addition, the company has mastered carbon 13, carbon 14, copper 64 and other key nuclear number of large-scale preparation technology, and in the development of new nuclear numbers such as special 161 anti -47 plus 68 and other aspects of technological breakthroughs.

A：The company has now registered three types of medical equipment, two of which are Class III medical devices, such as the home pigment stereotactic radiotherapy system (Tom C) and the mobile digital photography X camera, and one of Class II medical devices.

A：In terms of radioactive sources, the company has successfully realized the localization and listing of 6 radioactive sources, including carbon 14, Nie 63 1192 after the manor and other products, as well as industrial use 22 yuan. Not only consolidated the original leading position, but also marched into high-end equipment such as wide and thick hot-rolled plate online mapping instrument, and explored the reuse of retired radioactive sources, and achieved positive results.

A：The main idea of future scientific and technological innovation is to accelerate the strategy of market-oriented scientific and technological innovation system, adhere to five principles, including serving the national strategy, independent scientific and technological innovation, and undertaking the mission of state-owned enterprises; strengthen overall planning and forward-looking R & D layout; highlight market orientation and promote The market-oriented innovation system accelerates the creation of new quality productivity; attaches importance to human resources, activates the main body of innovation; and the collaborative innovation of production and research.

A：In the future, in terms of audit, the company will speed up the domestic large-scale preparation around the key audit of the existing market scale, and aim at the advance layout of the new potential audit in the future. In terms of nuclear medical equipment, the company will promote the localization of domestic Tom C, increase the localization process of stripper in stages, promote gamma knife and other equipment, and enrich the product line of respiratory diagnosis and charge number analysis diagnosis. In addition, detailed plans and goals have been formulated in the areas of radiation sources and their applications, and the combination of artificial intelligence and nuclear technology.

A：China's strategic plan for the period of Tongfu 15 is based on the outline of the 10th five-year Plan for National Economic and Social Development, and we will further refine and improve it on the basis of studying and understanding the requirements of the state. At present, according to the previous thinking, we have reported the key points of the strategic plan for the 15 period as follows: after more than 40 years of development, China Tongfu has formed six major development foundations, including unique nuclear industry system support, perfect layout capability, stable supply chain system, complete professional talent echelon, rich accumulation of industry resources and first-mover advantage. In the 15th Plan, our mission is to benefit the science and technology enabling industry, our vision is to become a leader in the nuclear technology application industry, and our values are responsibility, safety, innovation and excellence. We have formulated clear overall goals and plans for seven business segments, and plan to achieve 20 landmark results in overall coordination, innovation-driven, market development, industrial layout, and capital operation.

A：The development path of China Tongfu is to co-ordinate the source, strengthen the core and expand the application. Specifically, we will strengthen the core by enhancing the leading position in the radioactive source of cooperative drugs, while strengthening the supply capacity of key raw materials (such as isotopes and radiation technology), and expanding the market space in the fields of nuclear medical equipment, nuclear medicine overall solutions and irradiation technology applications. In order to achieve revenue targets, we have identified key tasks and resource guarantees to ensure that all physical targets can be successfully achieved.

A：During the 15 period, the radiopharmaceutical industry will adhere to new drug research and development as the core, market development as the focus, supporting services as the starting point, international operation as a breakthrough, continue to enhance the leading position of domestic drug release, and help the construction of a healthy China. Key measures include increasing cooperation and introduction of new drugs. Expand indications through new and old drugs to cover more patient groups; Improve the layout of medical centers and build an efficient and collaborative drug delivery network service system; Strengthen the professional and composite construction of marketing teams to promote the development of nuclear medicine and the promotion of solutions; Carry out CMO and CSO business services to build a distinctive drug delivery industry service system; Actively promote the overseas export of drug delivery lines and provide Chinese solutions.

A：In the field of respiratory diagnosis and industrial extension, we will adhere to the up and down extension of the left and right supporting, expand and optimize the stock product market, co-ordinate brand sales and after-sales construction, to ensure the stable supply of related products and orderly expansion. Key measures also include expanding production capacity and upgrading production lines according to market demand, and building a full-chain data platform for raw material production, storage and distribution; Complete the research and development of multi-specification carbon 13 breathing experimental products and expand the number of users; Relying on hospital digestive resources to extend to relevant diagnosis and treatment products; Promote the research of stable isotope drugs such as BNCT drugs and make efforts in industrial application; Restructure overseas marketing channels to improve market coverage.

A：In the next 1 to 2 years, the company will make adjustments according to the outline of the Tenth Five-Year Plan announced by the state, and plans to complete the preparation and finalization of the plan in the first half of the year. At the same time, it will pay close attention to the publicity and implementation training of planning interpretation, transform the planning into work plans and assessment objectives, and strengthen the details and execution of the work plans. In addition, the company also plans to make changes in the market development system, strengthen brand promotion, channel construction and after-sales service, in order to enhance the control of sales channels and brand influence.

A：During the 14th Five-Year Plan period, the company will study and possibly invest in mergers and acquisitions to strengthen the industrial chain in accordance with the requirements of chain extension, chain supplement and strong chain. Regarding the expected operating indicators for the next 1 to 2 years, as the plan has not been reviewed by the board of directors and is subject to information disclosure restrictions, the specific indicators cannot be disclosed for the time being, and will be finalized in June or July and announced in due course after review by the board of directors.

A：Thank you for asking this question. At present, China's Hyde William, a subsidiary of China Tongfu, has laid out several key products and made corresponding preparations for suppliers of large ammunition raw materials and developers of electronic special gas in the next step, but the specific details have not yet been disclosed. For electronic special gas, such as high purity carbon 12 electronic special gas, with the development of the situation, the problem will be more clear. But what is clear is that there is basically no risk of supply chain restrictions at present.